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Intraperitoneal administration of 100 mgk g
71 (body weight) of tumour necrosis factor-a to rats for 8 consecutive days
resulted in a signiﬁcant decrease in protein content, which was concomitant with a reduction in DNA content. Interestingly,
the protein/DNA ratio was unchanged in the skeletal muscle of the tumour necrosis factor-a-treated animals as compared
with the non-treated controls. Analysis of muscle DNA fragmentation clearly showed enhanced laddering in the skeletal
muscle of tumour necrosis factor-a-treated animals, suggesting an apoptotic phenomenon. In a different set of experiments,
mice bearing a cachexia-inducing tumour (the Lewis lung carcinoma) showed an increase in muscle DNA fragmentation (9.8-
fold) as compared with their non-tumour-bearing control counterparts as previously described. When gene-deﬁcient mice for
tumour necrosis factor-a receptor protein I were inoculated with Lewis lung carcinoma, they were also affected by DNA
fragmentation; however the increase was only 2.1-fold. These results suggest that tumour necrosis factor-a partly mediates
DNA fragmentation during experimental cancer-associated cachexia.
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Tumour necrosis factor-a (TNF) is a cytokine synthetised and
released by blood monocytes and tissue macrophages in response
to invasive stimuli, which exerts diverse metabolic effects (see
Evans et al, 1989; Argile ￿s et al, 1997 for a review). Although a large
body of evidence suggests that this cytokine participates in the
protein wasting and loss of nitrogen associated with cachectic
situations (Argile ￿s et al, 1997; Argile ￿s and Lo ￿pez-Soriano, 1999),
the mechanisms underlying such actions still remain obscure. Both
in man and mouse, TNF binds as homotrimer to two kinds of
receptors, TNFR1 (p55) and TNFR2 (p75) (Hohman et al, 1989);
in addition, lymphotoxin-a (LTa or TNF-b) also binds to the same
receptors. The pleiotropic functions of TNF can be partially
explained by the presence of its receptors in almost all types of
nucleated cells. The expression of the genes encoding the two
receptors is differentially regulated in different cells. TNFR1 is
expressed constitutively and plays a central role in many biological
processes, whereas less is known about TNFR2 expression (see
Vandenabeele et al, 1995 for a review).
Cancer cachexia is perhaps the most common manifestation of
advanced malignant disease. Cachexia occurs in the majority of
cancer patients before death, and is responsible for the death of
22% of these patients (Warren, 1932), although lower percentages
have been considered in more recent publications (Dworzak et al,
1998). The abnormalities associated with cancer cachexia include
anorexia, weight loss, muscle loss and atrophy, anaemia and altera-
tions in metabolism (see Argile ￿s et al, 1997, for review). The degree
of cachexia is inversely correlated with the survival time of the patient
and it always implies a poor prognosis (Harvey et al, 1979; Nixon et
al, 1980; De Wys, 1985). Perhaps asthenia is one of the most relevant
characteristics of cachexia, reﬂecting the extensive muscle waste that
takes place in the cachectic cancer patient (Argile ￿s et al, 1992), and is
also characterised by a general weakness as well as physical and
mental fatigue (Adams and Victor, 1981). Actually, body protein
depletion is one of the main trends of cachexia and it involves not
only skeletal muscle but it also affects cardiac proteins, resulting in
alterations in heart performance (Drott et al, 1986).
Apoptosis, the programmed type of cell death, is an important
physiological process in the development and homeostasis of multi-
cellularorganisms. Apoptotic cell death is characterised by a common
pattern of morphological alterations such as chromatin condensa-
tion, membrane blebbing, DNA fragmentation and cell shrinkage
(Huppertz et al, 1999). In cardiac muscle, apoptosis has been recog-
nised as a component of many common pathologies including
chronic heart failure, cardiac sudden death, viral myocarditis and
ischaemia (Tanaka et al, 1994; Itoh et al, 1996; Kajstura et al,
1996). Moreover, during chronic heart failure, rat skeletal muscle
atrophy has been related to apoptosis (Dalla Libera et al, 1999).
Indeed, apoptosis has already been described associated with skeletal
muscle atrophy (Allen et al, 1997; Tews and Goebel, 1997; Tews et al,
1997) and other diseases (see Sandri and Carraro, 1999, for review).
During cancer cachexia, the activation of the ubiquitin-depen-
dent proteolytic pathway seems to be responsible for the muscle
protein mobilisation (Argile ￿s and Lo ￿pez-Soriano, 1996). Recently,
a link between the apoptosome and the proteasome pathway has
been described (Dimmeler et al, 1999). In addition, we have
demonstrated that during experimental cancer cachexia, DNA frag-
mentation is increased in skeletal muscle (Van Royen et al, 2000).
Therefore, it was the aim of the present investigation to examine if
cytokines, TNF in particular, synthetised during the evolution of
the tumour-induced cachectic process, were involved in the
changes in skeletal muscle DNA content and integrity.
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Animals, tumour inoculation and TNF treatment
Male C57BL/6 mice (Criffa, Barcelona, Spain) weighing about 25 g
were used. Mice were divided into two groups, namely controls
and tumour hosts. The latter received an intramuscular (left thigh)
inoculum of 5610
5 Lewis lung carcinoma cells obtained from
exponential tumours. The development of a nodule at the side of
the injection, growing in size up to almost 20% of the animal
weight in 2 weeks, was considered as an index of effectiveness of
the inoculation. Nearly 100% of the injected animals developed
hind-leg tumours, and all of them were affected by lung metastasis
from day 7 onwards. On day 15 after tumour transplantation,
animals were weighed and anaesthetised with ketamine/xylacine
(Imalgene and Rompun respectively).
Concerning TNFRI-deﬁcient mice, homozygous mice for a
disrupted TnfrI allele (TnfrI8) were used. The gene targeting vector
consisted of a genomic mouse DNA fragment (Rothe et al, 1993),
in which exons 2 and 3 and part of exon 4 of the TnfrI gene were
replaced by a neo cassette. This deletion disrupts the gene and
removes the coding information for the cysteine-rich domains I
and II of the receptor, which have been shown to be essential
for ligand binding (Banner et al, 1993). Germ-line transmitters of
the mutated TnfrI allele were crossed with C57BL/6 mice and the
resulting heterozygous mice interbred to yield homozygous mutant
offspring. The F1 generation displayed the expected mendelian
1:2:1 of wild-type (+/+), heterozygous (0/+) and homozygous
(0/0) mutant mice, indicating that TnfrI expression is not required
for normal embryonic development.
In the experiments involving chronic TNF treatment, female
Wistar rats (Interfauna Iberica) weighing 100–150 g were used.
TNF was given intraperitoneally for 8 days at a dose of
100 mgk g
71 per day (two administrations at 08:00 and 20:00 h).
Control animals received 0.5 ml of vehicle (physiological saline).
Human recombinant-derived TNF-a (speciﬁc activity
8.1610
6 um g
71 protein, purity 499% containing less than
0.137 ng mg
71 endotoxin) was generously given by BASF/Knoll
AG (Ludwigshafen, Germany).
All animals were maintained on a regular light-dark cycle (light
on from 08:00 to 20:00 h) and had free access to food and water.
The diet (BK Universal GJ/SL, Sant Vicenc ¸ del Horts, Barcelona,
Spain) consisted of 45.5–48.5% carbohydrate (3.5% absorbible
glucose, 43–45% starch), 18.5% protein and 3.1% fat (the residue
was non-digestible material).
All animal experiments have been carried out with ethical
committee approval. The ethical guidelines that were followed meet
the standards required by the UKCCCR guidelines (Workman et al,
1998).
Biochemicals
They were all reagent grade and obtained either from Roche
(Barcelona, Spain) or from Sigma Chemical Co. (St Louis, MO,
USA).
DNA and protein content
Samples of skeletal muscles were homogenised in an ammonium
hydroxide/Triton X-100 extraction buffer (supplemented with
protease inhibitors) and used for the determination of both protein
(Bradford, 1976) and DNA (Downs and Wilﬁnger, 1983) content.
DNA fragmentation assay
Gastrocnemius muscles were homogenised and incubated at 48ºC
overnight in Kauffman buffer (0.5 M TRIS, 2 mM EDTA, 10 mM
NaCl, 1% SDS) in the presence of 200 mgm l
71 of Proteinase K,
and DNA was extracted with phenol/chloroform. After ethanol
precipitation, the pellets were resuspended and the DNA integrity
was checked in a 2% agarose gel electrophoresis and ethidium
bromide staining. The percentage of DNA fragmentation was quan-
tiﬁed by scanning densitometry. Liver from 8-h anti-Fas antibody-
treated mice (Ogasawara et al, 1993) was used as a positive control
of DNA fragmentation.
Plasma TNF levels
Circulating TNF was evaluated by a murine immunoassay
(Genzyme, Cambridge, MA, USA).
Statistical analysis
Statistical analysis of the data was performed by means of the
Student’s t-test.
RESULTS
As can be seen in Table 1, chronic administration of TNF to rats
for 8 consecutive days results in a decrease (21%) in skeletal
muscle protein content (soleus). The cytokine also induces a simi-
lar decrease in muscle DNA content although the results do not
reach statistical signiﬁcance. Interestingly, the protein/DNA ratio
is unchanged as a result of TNF treatment. At this point, it seemed
that DNA was probably being degraded at a faster rate as a conse-
quence of TNF treatment. As can be seen in Figure 1, DNA
fragmentation is clearly induced by the cytokine; indeed it caused
an increase of 4.6-fold over the basal fragmentation observed in
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Table 1 Effect of chronic TNF treatment on protein and DNA content
in rat soleus muscles
Experimental DNA Protein Protein/
group mg (100 g ibw)
71 mg (100 g ibw)
71 DNA
Control 0.341+0.029 108.0+6.7 317+20
TNF treatment 0.268+0.047 85.0+4.1* 317+15
The results are mean values+s.e.m. for ﬁve animals in each group. Statistical signifi-
cance of the differences (Student’s t-test): *P50.05; ibw: initial body weight.
600
400
200
1                 2                3                4                  5               6
Figure 1 DNA laddering in rats chronically treated with hrTNF-a
(100 mgk g
71 body weight/day). Lane 1: DNA molecular weight marker;
lanes 2–5: 40 mg of gastrocnemius muscle DNA from control (lanes 2
and 3) and TNF-treated (lanes 4 and 5) rats respectively; lane 6: 20 mg
of liver DNA from anti-Fas-treated mice (positive control) The percentage
of DNA fragmentation was quantiﬁed by scanning densitometry.
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(Van Royen et al, 2000) demonstrating that during experimental
cancer cachexia, DNA fragmentation was an important event in
skeletal muscle. For this reason, we decided to investigate if TNF
was involved in this apoptotic event, since tumour-bearing animals
generally show high circulating levels of the cytokine (Costelli et al,
1993). Bearing all this in mind, in the following experiments we
used gene-deﬁcient mice for TNFRI protein (TNFRI KO). As can
be seen in Figure 2, tumour growth induced an important decrease
in gastrocnemius weight (26%) in wild-type animals. In the gene-
deﬁcient mice, however, tumour burden only caused a 13%
decrease in gastrocnemius weight (Figure 2). Interestingly, control
non-tumour-bearing gene-deﬁcient mice have a signiﬁcantly smal-
ler muscle mass (21%) as compared with the control wild-type
mice (Figure 2). Similarly, gastrocnemius total protein content
was clearly decreased (29%) by tumour burden in wild-type mice
as well as in the TNFRI KO mice (18%) (Table 2). The DNA
content was also decreased as a result of tumour growth in the
wild-type (39%) and in the TNFRI KO mice (30%) (Table 2).
Interestingly, the protein/DNA ratio was unchanged in the wild-
type mice as a result of tumour burden whereas in the gene-deﬁ-
cient mice tumour growth resulted in a signiﬁcant increase in
this ratio (Table 2).
Figure 3 shows the result of the DNA fragmentation analysis.
The Lewis lung carcinoma induced a marked increase in DNA frag-
mentation in wild-type mice (9.8-fold). The tumour also induced
an increase in DNA fragmentation in the gene-deﬁcient mice but
this was much more modest (2.1-fold). Interestingly, control gene
knockout mice have a higher rate of DNA fragmentation (3.9-fold)
than that observed in the control wild-type mice (Figure 3). The
circulating concentrations of TNF are shown in Table 3. It can
be seen that tumour growth results in an increase in circulating
cytokine both in wild-type (91%) and gene-deﬁcient (178%)
animals.
DISCUSSION
DNA fragmentation is a common feature of apoptotic cell death
and we have previously suggested that the muscle wasting that
accompanies cancer cachexia could be linked to an apoptotic
phenomenon by which muscle cells lose not only protein but also
DNA (Van Royen et al, 2000). Apoptosis has already been
described in human (Tews and Goebel, 1997; Tews et al, 1997)
and rat (Dalla Libera et al, 1999) atrophic muscle as well as in
insect muscle (Schwartz et al, 1993). In patients with malignant
tumours, anorexia, weight loss, emaciation and progressive altera-
tions of vital functions are common features associated with
cancer cachexia (De Wys, 1985). Although in some cases anorexia,
gastrointestinal obstruction or malabsorption are responsible for
the weight loss of cachectic patients (Balducci and Hardy, 1985),
it cannot be wholely attributed to these causes and therefore it
has been postulated to be due to a decrease in the energetic efﬁ-
ciency of the cancer patient. Among the factors involved in
decreasing the energetic efﬁciency, skeletal muscle protein turnover
seems to have a very signiﬁcant role as we have previously shown
(see Argile ￿s et al, 1997, for review). In addition, apoptosis also
seems to be present in cachectic muscle in different experimental
tumour models (Van Royen et al, 2000). The basic aim of the
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Figure 2 Effects of tumour growth on gastrocnemius weight in tumour-
bearing mice. Results are mg (100 g ibw
71) of initial body weight. Statisti-
cal signiﬁcance of the results: *P50,05; ***P50.001 (vs non-tumour);
...P50.001 (vs wild-type) n=5 for wild-type and KO, n=6 for tumour-
bearing mice. LLC: Lewis lung carcinoma.
Table 2 Protein and DNA content in mice gastrocnemius muscles
Experimental DNA Protein Protein/
group mg (100 g ibw)
71 mg (100 g ibw)
71 DNA
Wild-type 0.578+0.052 13.99+7.0 259+10
Wild-type+LLC 0.350+0.011** 99.2+1.3*** 286+12
TNFRI KO 0.588+0.031 112.0+3.5* 187+6**
TNFI KO+LLC 0.411+0.017## 92.2+3.3## 229+8##
The results are mean values+s.e.m. for four animals in each group. Statistical signifi-
cance of the differences (Student’s t-test): *P50.05, **P50.01, ***P50.001 (vs
wild-type); ##P50.01 (vs TNFRI KO). LLC: Lewis lung carcinoma; ibw: initial body
weight.
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Figure 3 DNA laddering in mice bearing the Lewis lung carcinoma. Lane
1: DNA molecular weight marker; lanes 2–5: 35 mg of gastrocnemius mus-
cle DNA from wild-type control (lanes 2 and 3) and tumour-bearing (lanes
4 and 5) respectively; lanes 6–9: 35 mg of gastrocnemius muscle DNA
from TNFRI KO mice, control (lanes 6 and 7) and tumour-bearing (lanes
8 and 9) respectively; lane 10: 20 mg of liver DNA from anti-Fas-treated
mice (positive control) The percentage of DNA fragmentation was quanti-
ﬁed by scanning densitometry.
Table 3 Plasma TNF levels in tumour-bearing mice
Experimental group TNF (pg ml
71)
Wild-type 22+7
Wild-type+LLC 42+2*
TNFRI KO 18+3
TNFRI KO+LLC 50+7**
TNF was determined by ELISA. The results are mean values+s.e.m. for ﬁve animals
in each group. Statistical signiﬁcance of the differences (Student’s t-test): *P50.05,
**P50.01 (vs wild-type).
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British Journal of Cancer (2002) 86(6), 1012–1016 ã 2002 Cancer Research UKpresent investigation was to see if the changes that occur in DNA
in skeletal muscle during experimental cancer cachexia are linked
to TNF. To test this hypothesis we have used two different experi-
mental approximations: chronic TNF administration to healthy rats
and experimental cancer cachexia (induced by the Lewis lung carci-
noma in mice) in gene-deﬁcient mice for TNFRI.
Different mediators have been suggested to account for cancer-
induced cachexia, but basically the presence of both tumoural and
humoural (mainly cytokines, TNF in particular) compounds is
associated with depletion of fat stores as well as of muscular tissues
(Argile ￿s and Lo ￿pez-Soriano, 1999). In fact, the balance between
pro-inﬂammatory cytokines, their soluble receptors and the anti-
inﬂammatory cytokines plays a key role in the development of
the cachectic syndrome (Argile ￿s and Lo ￿pez-Soriano, 1998). Our
research group has demonstrated that TNF is involved in the acti-
vation of the ubiquitin-dependent proteolysis that takes place
during tumour growth (Garcı ￿a-Martı ￿nez et al, 1994; Llovera et
al, 1996, 1998). We clearly show here that TNF is also involved
in triggering DNA fragmentation in muscle during cancer cachexia,
mainly through the TNFRI. Indeed, chronic administration of
recombinant human TNF, which can only bind rat TNFRI, clearly
induces DNA fragmentation, and the use of a tumour model
(where the levels of circulating TNF are highly increased) conﬁrm
this fact.
Indeed, the Lewis lung carcinoma is a cachectic tumour that
induces an important decrease in body weight without signiﬁcant
changes in food intake, at least in the two ﬁrst weeks of tumour
growth (Llovera et al, 1998). Because TNFRI is absent from the
cells of these animals, the data obtained here suggest that TNF
can be involved in the muscle apoptotic mechanisms triggered by
tumour growth through its binding with the TNFRI. However,
TNFRI is not the sole receptor responsible for transduction of
the death signal, even though it is the most important one. Under
certain circumstances, TNFRII also either enhances the TNFRI
death signal or, indeed, mediates death independently (Declercq
et al, 1998; Haridas et al, 1998; Weiss et al, 1998). The mechanism
of the TNFRII death signal has not been characterised. The results
clearly show that in the gene-deﬁcient mice apoptosis is not
induced by tumour growth to the same extent as in the wild-type
animals. In fact, TNF has been shown to trigger apoptosis in many
cell types (Obeid et al, 1993; Ohta et al, 1994; Sidoti-de-Fraisse et
al, 1998) including cardiac muscle (Krown et al, 1996). In addition,
a possible link between TNF and apoptosis has already been
reported in ‘fast’ skeletal muscles in chronic heart failure (Dalla
Libera et al, 1999). Interestingly high circulating levels of TNF
are detectable in both rat (Costelli et al, 1993) and mouse (Llovera
et al, 1998) tumour models used in this study.
Furthermore, TNF-treatment induces Bcl-2 dephosphorylation,
targeting this anti-apoptotic protein for degradation by the ubiqui-
tin proteolytic system (Dimmeler et al, 1999). Thus, TNF-induced
apoptosis could be mediated by different cellular responses (Liu et
al, 1996), which include the activation of TNFRI death domain
and, as a consequence, the caspase cascade and ampliﬁcation of
this apoptotic pathway by means of ubiquitin-dependent Bcl-2
degradation. Nevertheless, TNF binding to its receptors also
induces cell proliferation and survival signals mediated by Bcl-2
activation of NF-kB (Liu et al, 1996; Wang et al, 1996). Therefore,
cell survival depends on a delicate balance between the different
TNF signalling pathways. For this reason, future investigations in
our laboratory will concentrate on ascertaining the role of this
and other cytokines in the activation of the apoptotic process asso-
ciated with cancer cachexia in skeletal muscle.
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